Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2020

View Archived Issues

Gaining insights into loss of function

Mice and men and estrogen

TLC submits IND application in Taiwan for inhalable liposomal hydroxychloroquine for COVID-19

New model displays transition to cardiac failure and reverse modeling

First patient dosed in phase I/II study of PRGN-2009

Positive data presented from phase II study of F-351 in China

Sichuan Kelun-Biotech Biopharmaceutical synthesizes new camptothecin derivatives

New CACNA2D ligands discovered at Sichuan Haisco Pharmaceutical

Gargamel (Zhuhai) Biotech discovers JAK-1 inhibitors

New MAP2K1 inhibitors patented by Betta Pharmaceuticals

CSPC Zhongqi Pharmaceutical Technology describes PROTAC BRD4 degradation inducers

CytoDyn presents update on its HIV programs

Dosing initiates in phase Ib study of plonmarlimab in Chinese patients with RA

Discovery of novel MAbs as promising COVID-19 immunotherapies

Neurotransmitter-derived synthetic lipids for delivery of BBB-impermeable cargos into the brain

Microfibrillar-associated glycoprotein 4 is a biomarker of alcoholic liver disease-related fibrosis

Targeting nuclear transport protein could lead to opioid alternatives

Improved oxygenation observed in COVID-19 patients treated with icatibant

UNITY presents 12-week data from phase II study of UBX-0101 in painful osteoarthritis of the knee

Interim analysis data from ODYSSEY study of tradipitant in COVID-19 pneumonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...